Published in Bull World Health Organ on May 01, 2004
Trade and public health: facing the challenges of globalisation. J Epidemiol Community Health (2006) 1.10
The association of beliefs about heredity with preventive and interpersonal behaviors in communities affected by podoconiosis in rural Ethiopia. Am J Trop Med Hyg (2012) 1.08
Management of intellectual property rights in India: An updated review. J Nat Sci Biol Med (2011) 0.75
The Governance of Genomic Information: Will it Come of Age? Genomics Soc Policy (2006) 0.75
Grand challenges in global mental health. Nature (2011) 8.40
Top ten biotechnologies for improving health in developing countries. Nat Genet (2002) 8.12
Grand challenges in global health: community engagement in research in developing countries. PLoS Med (2007) 4.75
Brazilian health biotech--fostering crosstalk between public and private sectors. Nat Biotechnol (2008) 2.57
India's health biotech sector at a crossroads. Nat Biotechnol (2007) 2.53
Ethics and SARS: lessons from Toronto. BMJ (2003) 2.39
Grand challenges in global health: the ethical, social and cultural program. PLoS Med (2007) 2.02
Chinese health biotech and the billion-patient market. Nat Biotechnol (2008) 2.00
DNA patents and diagnostics: not a pretty picture. Nat Biotechnol (2010) 1.95
A tough transition. Nature (2007) 1.75
Global health. Stagnant health technologies in Africa. Science (2010) 1.68
Grand challenges in global health: engaging civil society organizations in biomedical research in developing countries. PLoS Med (2007) 1.68
Nanotechnology and the developing world. PLoS Med (2005) 1.66
Small but tenacious: South Africa's health biotech sector. Nat Biotechnol (2009) 1.63
Race and ancestry in biomedical research: exploring the challenges. Genome Med (2009) 1.55
Grand challenges in global health: ethical, social, and cultural issues based on key informant perspectives. PLoS Med (2007) 1.50
Needed: models of biotechnology intellectual property. Trends Biotechnol (2002) 1.48
Global health challenges: the need for an expanded discourse on bioethics. PLoS Med (2005) 1.46
The three main monotheistic religions and gm food technology: an overview of perspectives. BMC Int Health Hum Rights (2009) 1.45
Innovative health service delivery models in low and middle income countries - what can we learn from the private sector? Health Res Policy Syst (2010) 1.44
The missing ingredient in medicine patent pools. Lancet (2009) 1.43
Grand challenges: Integrating mental health care into the non-communicable disease agenda. PLoS Med (2013) 1.42
Conclusions: promoting biotechnology innovation in developing countries. Nat Biotechnol (2004) 1.38
South Africa--blazing a trail for African biotechnology. Nat Biotechnol (2004) 1.34
Whole genome scanning: resolving clinical diagnosis and management amidst complex data. Pediatr Res (2009) 1.29
Science community: scientific diasporas. Science (2006) 1.29
State of academic knowledge on toxicity and biological fate of quantum dots. Toxicol Sci (2009) 1.23
The global alliance for chronic diseases. Science (2009) 1.23
Harnessing stem cells for health needs in India. Cell Stem Cell (2008) 1.19
Biotechnology and the UN's Millennium Development Goals. Nat Biotechnol (2003) 1.19
Recalibrating intellectual property rights to enhance translational research collaborations. Sci Transl Med (2012) 1.18
Regenerative medicine in Brazil: small but innovative. Regen Med (2010) 1.12
Genomics--a global public good? Lancet (2003) 1.11
Shared principles of ethics for infant and young child nutrition in the developing world. BMC Public Health (2010) 1.11
Introduction: promoting global health through biotechnology. Nat Biotechnol (2004) 1.10
Introducing new technologies: protecting subjects of surgical innovation and research. World J Surg (2003) 1.09
Cuba--innovation through synergy. Nat Biotechnol (2004) 1.06
"Harnessing genomics to improve health in India" - an executive course to support genomics policy. Health Res Policy Syst (2004) 1.06
Priority setting for orphan drugs: an international comparison. Health Policy (2010) 1.04
Lessons on ethical decision making from the bioscience industry. PLoS Med (2006) 1.03
The CNCDs and the NTDs: blurring the lines dividing noncommunicable and communicable chronic diseases. PLoS Negl Trop Dis (2008) 1.02
Public engagement on global health challenges. BMC Public Health (2008) 1.01
Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nat Rev Genet (2008) 1.01
Genomic medicine and developing countries: creating a room of their own. Nat Rev Genet (2008) 0.99
Incentives for organ donation: proposed standards for an internationally acceptable system. Am J Transplant (2011) 0.99
South-South entrepreneurial collaboration in health biotech. Nat Biotechnol (2010) 0.99
Indian biotechnology--rapidly evolving and industry led. Nat Biotechnol (2004) 0.98
A survey of South-North health biotech collaboration. Nat Biotechnol (2009) 0.96
The next steps for genomic medicine: challenges and opportunities for the developing world. Nat Rev Genet (2008) 0.96
South Africa: from species cradle to genomic applications. Nat Rev Genet (2008) 0.96
Theatre as a public engagement tool for health-policy development. Health Policy (2005) 0.96
Science-based health innovation in sub-Saharan Africa. BMC Int Health Hum Rights (2010) 0.95
Patent landscaping for life sciences innovation: toward consistent and transparent practices. Nat Biotechnol (2013) 0.93
"Harnessing genomics to improve health in Africa" - an executive course to support genomics policy. Health Res Policy Syst (2005) 0.92
The scientific muscle of Brazil's health biotechnology. Nat Biotechnol (2004) 0.91
Health biotechnology in China--reawakening of a giant. Nat Biotechnol (2004) 0.91
Strengthening the role of genomics in global health. PLoS Med (2004) 0.91
Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators. Health Res Policy Syst (2012) 0.91
Harnessing genomics to improve health in the Eastern Mediterranean Region - an executive course in genomics policy. Health Res Policy Syst (2005) 0.90
Cultivating regenerative medicine innovation in China. Regen Med (2010) 0.90
South Korean biotechnology--a rising industrial and scientific powerhouse. Nat Biotechnol (2004) 0.90
North-South partnerships--a study of Canadian firms. Nat Biotechnol (2007) 0.89
Venture funding for science-based African health innovation. BMC Int Health Hum Rights (2010) 0.89
Innovative drugs and vaccines in China, India and Brazil. Nat Biotechnol (2012) 0.86
The use of race, ethnicity and ancestry in human genetic research. Hugo J (2011) 0.86
Regenerative medicine and the developing world. PLoS Med (2006) 0.86
Globetrotting firms: Canada's health biotechnology collaborations with developing countries. Nat Biotechnol (2009) 0.86
Avian influenza and pandemics. N Engl J Med (2005) 0.86
The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries. BMC Public Health (2011) 0.85
Gene patents--more evidence needed, but policymakers must act. Nat Biotechnol (2007) 0.85
From diversity to delivery: the case of the Indian Genome Variation initiative. Nat Rev Genet (2008) 0.85
The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan. BMC Int Health Hum Rights (2010) 0.85
Biotechnology patents: strategies for meeting economic and ethical concerns. Nat Genet (2002) 0.84
Cuba and Brazil: an important example of South-South collaboration in health biotechnology. MEDICC Rev (2010) 0.84
Africa's largest long-lasting insecticide-treated net producer: lessons from A to Z Textiles. BMC Int Health Hum Rights (2010) 0.83
Factors influencing agbiotech adoption and development in sub-Saharan Africa. Nat Biotechnol (2012) 0.83
Science-based health innovation in Uganda: creative strategies for applying research to development. BMC Int Health Hum Rights (2010) 0.83
Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men. BJU Int (2005) 0.82
The emergence of Egyptian biotechnology from generics. Nat Biotechnol (2004) 0.82
Human-animal chimeras for vaccine development: an endangered species or opportunity for the developing world? BMC Int Health Hum Rights (2010) 0.82
Biotechnology to improve health in developing countries -- a review. Mem Inst Oswaldo Cruz (2004) 0.82
Legal and ethical approaches to stem cell and cloning research: a comparative analysis of policies in Latin America, Asia, and Africa. J Law Med Ethics (2004) 0.82
Stakeholder involvement in expensive drug recommendation decisions: an international perspective. Health Policy (2012) 0.82
Science-based health innovation in Rwanda: unlocking the potential of a late bloomer. BMC Int Health Hum Rights (2010) 0.81
The roles of a bioethicist on an organ transplantation service. Am J Transplant (2005) 0.81